SynthesisPLoS neglected tropical diseases2016
Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica: A Systematic Review.
Synthesis in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Prevalence and associated risk factors of human leishmaniasis in sub-Saharan Africa: an umbrella review.BMC infectious diseases · 2025Pooled it
- Knowledge, Attitudes, and Practices toward Cutaneous Leishmaniasis as a Neglected Tropical Disease among the General Population: A Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2025Pooled it
- Treatment outcomes of cutaneous leishmaniasis due to Leishmania aethiopica: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Diagnosis of visceral and cutaneous leishmaniasis using loop-mediated isothermal amplification (LAMP) protocols: a systematic review and meta-analysis.Parasites & vectors · 2022Pooled it
- Effectiveness of intralesional sodium stibogluconate for the treatment of localized cutaneous leishmaniasis at Boru Meda general hospital, Amhara, Ethiopia: Pragmatic trial.PLoS neglected tropical diseases · 2022Trial
- Ambiguities in cutaneous leishmaniasis classification and the need for consensus: Experience from Ethiopia.PLoS neglected tropical diseases · 2025Article
- Experiences of Individuals with Cutaneous Leishmaniasis Receiving Intralesional Sodium Stibogluconate or Liquid Nitrogen Cryotherapy in Addis Ababa, Ethiopia-A Cross-Sectional Study.Tropical medicine and infectious disease · 2025Article
- Unveiling the hidden burden: Exploring the psychosocial impact of cutaneous leishmaniasis lesions and scars in southern Ethiopia.PloS one · 2025Article
- Article
- An assessment of interobserver agreement on lesion size, morphology and clinical phenotype in cutaneous leishmaniasis caused byNIHR open research · 2025Article
- A case of adnexal cutaneous leishmaniasis in Washington DC.Journal of ophthalmic inflammation and infection · 2024Article
- Article
- Prevalence and risk factors of cutaneous leishmaniasis in a newly identified endemic site in South-Ethiopia.PloS one · 2024Article
- Health-related quality of life of adults with cutaneous leishmaniasis at ALERT Hospital, Addis Ababa, Ethiopia.PLoS neglected tropical diseases · 2023Article
- Treatment of Cutaneous Leishmaniasis with Sodium Stibogluconate and Allopurinol in a Routine Setting in Ethiopia: Clinical and Patient-Reported Outcomes and Operational Challenges.Tropical medicine and infectious disease · 2023Article
- Burden of neglected tropical diseases and access to medicine and diagnostics in Ethiopia: a scoping review.Systematic reviews · 2023Article
- Article
- Cutaneous leishmaniasis in a newly established treatment centre in the Lay Gayint district, Northwest Ethiopia.Skin health and disease · 2023Article
- The Extraordinary Case of a Woman with a 30-Year-Long Diffuse Leishmaniasis Cured with One Single Ampoule of Intranasal Pentavalent Antimoniate.Pathogens (Basel, Switzerland) · 2023Article
- Making the Most of Its Short Reads: A Bioinformatics Workflow for Analysing the Short-Read-Only Data ofBiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Leishmania aethiopica is the etiological agent of cutaneous leishmaniasis (CL) in Ethiopia and can cause severe and complicated cases such as diffuse CL (DCL), mucocutaneous leishmaniasis or extensive CL, requiring systemic treatment. Despite the substantial burden, evidence-based treatment guidelines are lacking. We conducted a systematic review of clinical studies reporting on treatment outcomes of CL due to L aethiopica in order to help identify potentially efficacious medications on CL that can be taken forward for clinical trials. We identified a total of 24 records reporting on 506 treatment episodes of CL presumably due to L aethiopica. The most commonly used drugs were antimonials (n = 201), pentamidine (n = 150) and cryotherapy (n = 103). There were 20 case reports/series, with an overall poor study quality. We only identified two small and/or poor quality randomized controlled trials conducted a long time ago. There were two prospective non-randomized studies reporting on cryotherapy, antimonials and pentamidine. With cryotherapy, cure rates were 60-80%, and 69-85% with antimonials. Pentamidine appeared effective against complicated CL, also in cases non-responsive to antimonials. However, all studies suffered from methodological limitations. Data on miltefosine, paromomycin and liposomal amphotericin B are extremely scarce. Only a few studies are available on DCL. The only potentially effective treatment options for DCL seem to be antimonials with paromomycin in combination or pentamidine, but none have been properly evaluated. In conclusion, the evidence-base for treatment of complicated CL due to L aethiopica is extremely limited. While antimonials remain the most available CL treatment in Ethiopia, their efficacy and safety in CL should be better defined. Most importantly, alternative first line treatments (such as miltefosine or paromomycin) should be explored. High quality trials on CL due to L aethiopica are urgently needed, exploring group sequential methods to evaluate several options in parallel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.